In-situ immune markers predict nivolumab (N) plus /-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial

被引：2
|
作者：
Meylan, M.
Sun, C-M.
Elaidi, R-T.
Moreira, M.
Bougouin, A.
Verkarre, V.
Bennamoun, M.
Chevreau, C. M.
Borchiellini, D.
Barthelemy, P.
Pannier, D.
Maillet, D.
Goupil, M. Gross
Tournigand, C.
Braychenko, E.
Phan, L.
Oudard, S.
Fridman, W-H.
Sautes-Fridman, C.
Vano, Y-A.
机构：
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1451MO
引用
收藏
页码：S1207 / S1207
页数：1
相关论文
共 50 条
  • [31] A phase I trial to assess the biologic effect of CBM588 (Clostridium butyricum) in combination with nivolumab plus ipilimumab (nivo/ipi) in patients with metastatic renal cell carcinoma (mRCC)
    Bergerot, Paulo Gustavo
    Dizman, Nazli
    Ruel, Nora
    Frankel, Paul Henry
    Hsu, Joann
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [32] Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).
    Lee, Chung-Han
    Shah, Amishi Yogesh
    Hsieh, James J.
    Rao, Arpit
    Pinto, Alvaro
    Bilen, Mehmet Asim
    Cohn, Allen Lee
    Di Simone, Christopher
    Shaffer, David R.
    Sarrio, Regina Girones
    Ribe, Sara Gunnestad
    Wu, Jane
    Schmidt, Emmett, V
    Perini, Rodolfo F.
    Kubiak, Peter
    Smith, Alan D.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Ipilimumab and nivolumab (I plus N) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world review in North West of England, United Kingdom.
    Allison, Jennifer
    Griffiths, Richard
    Waddell, Tom
    Pillai, Manon Rhys
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [34] Healthcare resource utilization (HCRU) and costs for patients (pts) with metastatic renal cell carcinoma (mRCC) receiving first-line (LOT1) pembrolizumab plus axitinib (P plus A) or ipilimumab plus nivolumab (I plus N).
    Shah, Neil J.
    Shinde, Reshma
    Moore, Kristin
    Sainski-Nguyen, Amy
    Le, Lisa
    Cao, Feng
    Song, Rui
    Singhal, Puneet
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] CheckMate 214: Efficacy and safety of nivolumab plus ipilimumab (N plus I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups
    Escudier, B.
    Tannir, N. M.
    McDermott, D. F.
    Frontera, O. A.
    Melichar, B.
    Plimack, E. R.
    Barthelemy, P.
    George, S.
    Neiman, V.
    Porta, C.
    Choueiri, T. K.
    Powles, T.
    Donskov, F.
    Salman, P.
    Kollmannsberger, C. K.
    Rini, B.
    Mekan, S.
    McHenry, M. B.
    Hammers, H. J.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN plus EVE in patients with metastatic renal cell carcinoma
    Lee, C-H.
    Motzer, R. J.
    Glen, H.
    Michaelson, M. D.
    Larkin, J.
    Minoshima, Y.
    Kanekiyo, M.
    Dairiki, R.
    Sachdev, P.
    Dutcus, C. E.
    Funahashi, Y.
    Voss, M. H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [37] Final results on efficacy and patient reported outcomes (PRO) of a randomized phase II trial investigating nivolumab switch-maintenance after TKI induction in metastatic clear cell renal cell carcinoma (mRCC) patients (NIVOSWITCH)
    Darr, C.
    Zschaebitz, S.
    Ivanyi, P.
    Wirth, M.
    Staib, P.
    Schostak, M.
    Mueller, L.
    Metz, M.
    Bergmann, L.
    Steiner, T.
    Lorch, A.
    Schuett, P.
    Rafiyan, M-R.
    Hellmis, E.
    Hinke, A.
    Maenz, M.
    Meiler, J.
    Kretz, T.
    Floercken, A.
    Gruenwald, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S700 - S700
  • [38] Final results on efficacy and patient reported outcomes (PRO) of a randomized phase II trial investigating nivolumab switch-maintenance after TKI induction in metastatic clear cell renal cell carcinoma (mRCC) patients (NIVOSWITCH)
    Darr, Christopher
    Zschaebitz, Stefanie
    Ivanyi, Philipp
    Wirth, Manfred
    Staib, Peter
    Schostak, Martin
    Mueller, Lothar
    Metz, Michael
    Bergmann, Lothar
    Steiner, Thomas
    Lorch, Anja
    Schuett, Philipp
    Rafiyan, Mohammad-Reze
    Hellmis, Eva
    Hinke, Axel
    Maenz, Martin
    Meiler, Johannes
    Kretz, Thomas
    Floercken, Anne
    Gruenwald, Viktor
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 100 - 100
  • [39] ESTIMATING LONG-TERM SURVIVORSHIP RATES FOR PREVIOUSLY UNTREATED INTERMEDIATE OR POOR (I/P) RISK ADVANCED RENAL CELL CARCINOMA (ARCC) PATIENTS TREATED WITH NIVOLUMAB PLUS IPILIMUMAB (NIVO plus IPI): ANALYSES FROM THE CHECKMATE 214 TRIAL
    Paly, V
    George, S.
    Youn, J. H.
    Borrill, J.
    Ejzykowicz, F.
    May, J. R.
    Kurt, M.
    VALUE IN HEALTH, 2022, 25 (01) : S210 - S210
  • [40] Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial
    Motzer, Robert J.
    Russo, Paul
    Grunwald, Viktor
    Tomita, Yoshihiko
    Barthelemy, Philippe
    Goh, Jeffrey C.
    Cutuli, Hernan Javier
    Simsek, Burcin
    Spiridigliozzi, Julia
    Chudnovsky, Aleksander
    Bex, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345